SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals gains on reporting 9% rise in Q3 consolidated net profit

22 Jan 2013 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 71.00, up by 0.10 points or 0.14% from its previous closing of Rs. 70.90 on the BSE.

The scrip opened at Rs. 71.40 and has touched a high and low of Rs. 72.75 and Rs. 70.40 respectively. So far 80268 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 78.95 on 12-Sep-2012 and a 52 week low of Rs. 37.10 on 24-Jan-2012.

Last one week high and low of the scrip stood at Rs. 72.90 and Rs. 68.10 respectively. The current market cap of the company is Rs. 1346.95 crore.

The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 7.76% and 18.11% respectively.

Alembic Pharmaceuticals has reported results for third quarter ended December 31, 2012.

On the consolidated basis, the company has reported 9.13% rise in its net profit at Rs 48.27 crore for the quarter as compared to Rs 44.23 crore for the same quarter in the previous year.  However, total income of the company has decreased by 3.36% at Rs 369.28 crore for quarter under review as compared to Rs 382.12 crore for the quarter ended December 31, 2011.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

784.95 36.05 (4.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×